Clinical Validation of Companion Diagnostics

Abstract

Companion diagnostics (CDx) -- in vitro diagnostic devices that identify patients most likely to benefit from, or at risk of harm from, a specific therapeutic product -- are the operational backbone of precision medicine, translating genomic biomarker discoveries into actionable clinical patient selection tools co-developed with their paired therapeutic. EMA and FDA require CDx co-development and simultaneous approval with their paired therapeutic for biomarker-selected indications, establishing a co-regulatory framework unique among medical devices. The CDx validation process - encompassing analytical validation (assay accuracy; precision; reproducibility; limit of detection), clinical validation (biomarker-response correlation in clinical trial populations), and clinical utility (demonstrated patient outcome improvement from CDx-guided treatment selection) -- is methodologically distinct from both pharmaceutical clinical trials and standard IVD validation. This study systematically evaluated 284 CDx clinical validation studies (2,840 CDx-drug-outcome data points; Estonia, Italy, and France precision diagnostics groups; EGFR, HER2, PD-L1, MSI, BRCA, KRAS, ALK, and TMB companion diagnostics; 2015-2025) analysing validation methodology quality, analytical performance metrics, clinical concordance, and regulatory submission outcomes. A Companion Diagnostic Validation Quality Index (CDVQI) integrating analytical validation completeness, clinical concordance quality, clinical utility evidence, and regulatory compliance predicted successful CDx regulatory approval with r = +0.84 and AUC = 0.884